The E.W. Scripps Company (SSP)
NASDAQ: SSP · Real-Time Price · USD
2.980
+0.080 (2.76%)
At close: Aug 4, 2025, 4:00 PM
3.030
+0.050 (1.68%)
After-hours: Aug 4, 2025, 4:20 PM EDT
Blueprint Medicines Stock Forecast
Stock Price Forecast
The 2 analysts that cover Blueprint Medicines stock have a consensus rating of "Buy" and an average price target of $6.00, which forecasts a 101.34% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $8.00.
Price Target: $6.00 (+101.34%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Blueprint Medicines stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $2.8 → $4 | Hold | Maintains | $2.8 → $4 | +34.23% | Jul 15, 2025 |
| Benchmark | Benchmark | Strong Buy Maintains $7 → $8 | Strong Buy | Maintains | $7 → $8 | +168.46% | Mar 13, 2025 |
| Benchmark | Benchmark | Strong Buy Maintains $11 → $7 | Strong Buy | Maintains | $11 → $7 | +134.90% | Nov 5, 2024 |
| Benchmark | Benchmark | Strong Buy Maintains $14 → $11 | Strong Buy | Maintains | $14 → $11 | +269.13% | Aug 12, 2024 |
| Benchmark | Benchmark | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +369.80% | May 13, 2024 |
Financial Forecast
Revenue This Year
2.20B
from 2.51B
Decreased by -12.42%
Revenue Next Year
2.41B
from 2.20B
Increased by 9.60%
EPS This Year
-0.79
from 1.01
EPS Next Year
-0.14
from -0.79
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.3B | 2.6B | 2.4B |
| Avg | 2.2B | 2.4B | 2.3B |
| Low | 2.1B | 2.3B | 2.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -8.2% | 16.8% | 1.3% |
| Avg | -12.4% | 9.6% | -6.4% |
| Low | -15.6% | 4.1% | -12.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.39 | 0.68 | -0.72 |
| Avg | -0.79 | -0.14 | -0.70 |
| Low | -1.16 | -0.79 | -0.68 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.